Company OverviewCoronary Artery DiseaseTechnical ResourcesEmployment OpportunitiesWhat's New


Boston, August 28, 2000/PRNewswire/...Percardia Inc., a privately held medical device company focused on the development of new therapeutic interventions (VCAB™ Surgical Delivery System, VSTENT™ Myocardial Implant) for the treatment of coronary artery disease, announced today the recent appointments of Laurence A. Roth, as Vice President of Development and Jill Wollins, PhD, as Vice President Regulatory Affairs and Quality Assurance.

Mr. Roth joins Percardia from Focal. Inc., where he managed product and business development activities of that company's proprietary polymer technology in cardiovascular and local drug delivery applications, among others. His experience includes over 20 years in product development and program management, including 13 years in the USCI Division for C. R. Bard, Inc. Mr. Roth brings to Percardia extensive experience in the development of complex medical devices for the cardiology market including 8 issued and pending patents in the areas of interventional cardiology and local drug delivery products. He earned a Bachelor of Science and Masters of Engineering degree from Rennselaer Polytechnic Institute and a Masters of Business Administration from Babson College.

Ms. Wollins joins Percardia from Agilent Technologies Inc. (formerly Hewlett Packard Medical Products Group) where she was responsible for global regulatory approvals for cardiovascular devices and internal quality systems and compliance. Previous to this she held progressive management positions at Stryker Biotech and Cardiac Pacemakers Inc., now a division of Guidant. Ms. Wollins completed a Postdoctoral Fellowship, Mayo Graduate School of Medicine and holds a PhD in Biomedical Engineering and a Master in Engineering from the University of Virginia, and a BS in Engineering from the University of Pennsylvania.

"We are pleased to have recruited both Mr. Roth and Ms. Wollins to join our senior management team," said Nancy Briefs, President and Chief Executive Officer of Percardia. "Larry's experience in interventional cardiology, product development, drug delivery and early stage startups provides the breadth of leadership experience necessary to lead our expanding development team. Ms. Wollins extensive experience with FDA cardiovascular devices including PMA's coupled with her PhD in Biomedical Engineering brings a well qualified background to our regulatory and clinical trial efforts. We look forward to both their contributions as we move from animal testing into clinical trials on our innovative ventricular revascularization technology in the future."Percardia's proprietary technology is based on intellectual property licensed from Peter J. Wilk, MD a noted surgeon and investor. The VCAB™ Surgical Delivery System creates a channel from the ventricle to the coronary artery by placing a stent through the heart wall. The company is backed by leading investors, including Atlas Venture, Crescendo Ventures, Vanguard Venture Partners and Medtronic Inc. For more information, please contact Percardia at 603.882.1803.

Press Releases | Events

Company | Coronary Artery Disease | Resources | Employment | What's New

Percardia Inc.
Heron Cove Office Park
10 Al Paul Lane, Suite 202
Merrimack, NH 03054
© 2001 Percardia Inc.